{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002569","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.309853+00:00","generated_at":"2026-06-02T22:07:48.148865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing","bullets":["Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.","Cash $22.1M at March 31, 2024; plus $30.6M from May 6 financing; projected cash into Q4 2025.","Soquelitinib Phase 1/1b PTCL: 39% ORR (5 CRs, 4 PRs) in 23 evaluable patients; disease control 61%.","Phase 3 registrational trial for soquelitinib in PTCL planned to start Q3 2024.","Ciforadenant Phase 1b/2 in RCC met predefined efficacy threshold; enrollment continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002569","json":"https://secwatch.observer/filing/0001171843-24-002569.json","markdown":"https://secwatch.observer/filing/0001171843-24-002569.md","text":"https://secwatch.observer/filing/0001171843-24-002569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/0001171843-24-002569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/f8k_050624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:07:48.148865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d66ef747894ff6f6d67bc15823fc4d61f275224","claim":"Corvus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/0001171843-24-002569-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}